Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.
Eur J Prev Cardiol
; 30(18): 1950-1962, 2023 12 21.
Article
in En
| MEDLINE
| ID: mdl-37409348
The long-term benefits of treatment with low-dose colchicine were estimated for 36 642 individuals with coronary heart disease, and compared with those of lipid- and blood pressurelowering therapy. On average, low-dose colchicine was estimated to lower the risk of cardiovascular disease in the next 10 years from 17.8 to 13.2% (a reduction of 4.6% points) and to afford 2.0 additional years of life without cardiovascular disease.Low-dose colchicine was estimated to be the most effective treatment in 49%, intensive blood pressurelowering therapy in 28%, and intensive lipid-lowering therapy in 23% of patients.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Coronary Artery Disease
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Myocardial Infarction
Type of study:
Guideline
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
Eur J Prev Cardiol
Year:
2023
Document type:
Article
Affiliation country:
Netherlands
Country of publication:
United kingdom